Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer

NCT00114816 is registered in ClinicalTrials.gov with Finnish Breast Cancer Group as lead sponsor.

NCT NCT00114816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00114816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer
Lead sponsor
Finnish Breast Cancer Group
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2004
Completion date
April 30, 2007
Enrollment
1,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer